Alain Matthey
Geneve, GE, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Uncovering a Genetic Polymorphism Located in Huntingtin Associated Protein 1 in Modulation of Central Pain Sensitization Signaling Pathways.
Journal: Frontiers in neuroscience
Published: November 02, 2021
Metabolomics reveals biomarkers in human urine and plasma to predict cytochrome P450 2D6 (CYP2D6) activity.
Journal: British journal of pharmacology
Published: December 09, 2020
Safety and immunogenicity of the epicutaneous reactivation of pertussis toxin immunity in healthy adults: a phase I, randomized, double-blind, placebo-controlled trial.
Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
Published: January 22, 2020
GABAergic modulation of secondary hyperalgesia: A randomized controlled 4-way crossover trial with the α2-subunit preferring GABA positive allosteric modulator, N-desmethyl-clobazam in healthy volunteers.
Journal: European journal of pain (London, England)
Published: September 23, 2019
Impact of CYP2D6 Functional Allelic Variations on Phenoconversion and Drug-Drug Interactions.
Journal: Clinical pharmacology and therapeutics
Published: July 24, 2017
The clobazam metabolite N-desmethyl clobazam is an α2 preferring benzodiazepine with an improved therapeutic window for antihyperalgesia.
Journal: Neuropharmacology
Published: January 07, 2016
The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.
Journal: The Lancet. Infectious diseases
Published: June 01, 2015
Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe.
Journal: The New England journal of medicine
Published: April 02, 2015
A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - a twelve month follow-up.
Journal: Journal of neuroimmunology
Published: March 19, 2015
P-glycoprotein: a clue to vitamin K antagonist stabilization.
Journal: Pharmacogenomics
Published: January 24, 2015
A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: May 13, 2014
Last Updated: 09/26/2026